JP2018503401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503401A5 JP2018503401A5 JP2017556795A JP2017556795A JP2018503401A5 JP 2018503401 A5 JP2018503401 A5 JP 2018503401A5 JP 2017556795 A JP2017556795 A JP 2017556795A JP 2017556795 A JP2017556795 A JP 2017556795A JP 2018503401 A5 JP2018503401 A5 JP 2018503401A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- constant region
- chain constant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 39
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 39
- 102000005962 receptors Human genes 0.000 claims description 38
- 108020003175 receptors Proteins 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 13
- 230000006907 apoptotic process Effects 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 11
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 9
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 8
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims description 7
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 claims description 7
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 claims description 7
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims description 7
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 claims description 7
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 claims description 7
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 7
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 5
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 101001055311 Equus asinus Immunoglobulin heavy constant alpha Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 101000648505 Homo sapiens Tumor necrosis factor receptor superfamily member 12A Proteins 0.000 claims description 3
- 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 claims description 3
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 3
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 3
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 3
- 108010014401 TWEAK Receptor Proteins 0.000 claims description 3
- 102000016946 TWEAK Receptor Human genes 0.000 claims description 3
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 claims description 3
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 claims description 3
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 3
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 3
- 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 claims description 3
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 3
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 claims description 3
- 230000001640 apoptogenic effect Effects 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims description 2
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 102400001107 Secretory component Human genes 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims description 2
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims 5
- 230000019552 anatomical structure morphogenesis Effects 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 22
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 241001024304 Mino Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105323P | 2015-01-20 | 2015-01-20 | |
| US62/105,323 | 2015-01-20 | ||
| PCT/US2016/014153 WO2016118641A1 (en) | 2015-01-20 | 2016-01-20 | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020158581A Division JP2021006044A (ja) | 2015-01-20 | 2020-09-23 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503401A JP2018503401A (ja) | 2018-02-08 |
| JP2018503401A5 true JP2018503401A5 (enExample) | 2019-02-28 |
| JP7179464B2 JP7179464B2 (ja) | 2022-11-29 |
Family
ID=56417700
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556795A Active JP7179464B2 (ja) | 2015-01-20 | 2016-01-20 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2020158581A Pending JP2021006044A (ja) | 2015-01-20 | 2020-09-23 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2022142258A Active JP7499813B2 (ja) | 2015-01-20 | 2022-09-07 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2024090474A Withdrawn JP2024113039A (ja) | 2015-01-20 | 2024-06-04 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020158581A Pending JP2021006044A (ja) | 2015-01-20 | 2020-09-23 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2022142258A Active JP7499813B2 (ja) | 2015-01-20 | 2022-09-07 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2024090474A Withdrawn JP2024113039A (ja) | 2015-01-20 | 2024-06-04 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10689449B2 (enExample) |
| EP (2) | EP3247728B1 (enExample) |
| JP (4) | JP7179464B2 (enExample) |
| KR (1) | KR102435324B1 (enExample) |
| CN (1) | CN107207601A (enExample) |
| AU (2) | AU2016209324B2 (enExample) |
| CA (1) | CA2972990A1 (enExample) |
| DK (1) | DK3247728T3 (enExample) |
| ES (1) | ES2806500T3 (enExample) |
| HU (1) | HUE051013T2 (enExample) |
| IL (3) | IL284430B2 (enExample) |
| NZ (1) | NZ732922A (enExample) |
| PL (1) | PL3247728T3 (enExample) |
| PT (1) | PT3247728T (enExample) |
| SG (2) | SG11201705116SA (enExample) |
| SI (1) | SI3247728T1 (enExample) |
| WO (1) | WO2016118641A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3041862T3 (da) | 2013-09-05 | 2020-07-27 | Igm Biosciences Inc | Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde |
| DK3105250T3 (da) | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | Multispecifikke iga-bindingsmolekyler |
| ES2717704T3 (es) | 2014-04-03 | 2019-06-24 | Igm Biosciences Inc | Cadena J modificada |
| PL3247728T3 (pl) | 2015-01-20 | 2020-11-16 | Igm Biosciences, Inc. | Cząsteczki wiążące receptor nadrodziny czynnika martwicy nowotworów (TNF) i ich stosowanie |
| SI3265575T1 (sl) | 2015-03-04 | 2021-08-31 | Igm Biosciences, Inc. | Vezne molekule CD20 in njihove uporabe |
| EP3274051A4 (en) | 2015-03-25 | 2018-08-22 | IGM Biosciences A/S | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| JP6811723B2 (ja) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
| SI3355913T1 (sl) | 2015-09-30 | 2025-01-31 | Igm Biosciences, Inc. | Vezalne molekule z modificirano j-verigo |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| KR102343742B1 (ko) | 2016-05-09 | 2021-12-24 | 아이쥐엠 바이오사이언스 인코포레이티드 | 항-pd-l1 항체 |
| CA3030659A1 (en) * | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| WO2018031400A1 (en) * | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| EP3360898A1 (en) * | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| EP3606949A1 (en) * | 2017-04-06 | 2020-02-12 | Universität Stuttgart | Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity |
| US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| CN108251443A (zh) * | 2018-01-23 | 2018-07-06 | 深圳市人民医院 | 一种tnfrsf10c重组质粒、制备方法及其应用 |
| WO2019157772A1 (zh) * | 2018-02-13 | 2019-08-22 | 和元生物技术（上海）股份有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
| CA3091140A1 (en) * | 2018-02-26 | 2019-08-29 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| BR112020017296A2 (pt) | 2018-03-01 | 2020-12-29 | Igm Biosciences, Inc. | Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| KR20210083260A (ko) * | 2018-10-23 | 2021-07-06 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다가 IgM- 및 IgA-Fc 기반 결합 분자 |
| CA3130754A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| CN114127111B (zh) | 2019-02-21 | 2024-09-10 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| EP3986920B1 (en) | 2019-06-24 | 2025-04-16 | Universität Stuttgart | Tnfr2 agonists with improved stability |
| CA3148881C (en) * | 2019-08-02 | 2025-06-17 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Anti-tumor necrosis factor 2 receptor antibodies and their use |
| AU2020329301A1 (en) | 2019-08-15 | 2022-02-17 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CN115443140A (zh) * | 2020-04-02 | 2022-12-06 | 苏州恒康生命科学有限公司 | 人ror-1抗体和抗ror-1-car-t细胞 |
| IL297029A (en) | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Multimeric binding compounds as pd-1 agonists |
| KR20230010221A (ko) * | 2020-05-12 | 2023-01-18 | 아이쥐엠 바이오사이언스 인코포레이티드 | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| JP7203870B2 (ja) | 2021-01-18 | 2023-01-13 | イビデン株式会社 | 組電池用熱伝達抑制シート及び組電池 |
| EP4314046A4 (en) * | 2021-04-01 | 2025-03-19 | ModernaTX, Inc. | Mucosal expression of antibody structures and isotypes by mRNA |
| GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
Family Cites Families (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| GB9015908D0 (en) | 1990-07-19 | 1990-09-05 | Celltech Ltd | Multivalent immunoglobulin |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| ATE314479T1 (de) | 1992-05-18 | 2006-01-15 | Genentech Inc | Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden |
| EP0614984B2 (en) | 1993-03-05 | 2010-11-03 | Bayer HealthCare LLC | Anti-TNF alpha human monoclonal antibodies |
| CA2139385C (en) | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
| AU697387C (en) | 1994-09-16 | 2006-03-02 | Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 | Polypeptides with Fc binding ability |
| US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| CN1900116A (zh) | 1995-01-26 | 2007-01-24 | 拜奥根Idec马萨诸塞公司 | 抗－LT－β－R抗体、含有该抗体的药用组合物及其制药应用 |
| IL116784A (en) | 1996-01-16 | 2000-01-31 | Hadasit Med Res Service | Device for examining viscoelasticity of a living or artificial tissue |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US20060269558A1 (en) | 1998-04-27 | 2006-11-30 | Murphy Gerald P | Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
| HK1041497B (en) | 1999-01-07 | 2004-06-18 | Zymogenetics, Inc. | Soluble receptor br43x2 and methods of using them for therapy |
| MXPA01008936A (es) | 1999-03-04 | 2003-07-21 | Human Genome Sciences Inc | Receptores 6 alfa y 6 beta del factor de necrosis tumoral. |
| EP1161261A1 (en) | 1999-03-11 | 2001-12-12 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii and methods of use |
| DE19963859A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| US7262005B1 (en) | 2000-02-04 | 2007-08-28 | Aurora Biosciences Corporation | Methods of protein destabilization and uses thereof |
| HUP0300369A2 (hu) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Többértékű antitestek és alkalmazásuk |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| CA2411828A1 (en) | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel co-stimulatory molecules |
| AU2001277531A1 (en) | 2000-07-10 | 2002-01-21 | Novartis Ag | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| AU2002327171A1 (en) | 2001-05-01 | 2003-01-02 | Medimmune, Inc. | Crystals and structure of synagis fab |
| WO2002094880A1 (fr) | 2001-05-18 | 2002-11-28 | Kirin Beer Kabushiki Kaisha | Anticorps anti-trail-r |
| US20050214210A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| MXPA03010728A (es) | 2001-05-25 | 2004-03-02 | Amgen Inc | Moleculas de proteina-2 relacionadas con b7 y uso de las mismas. |
| US7199227B2 (en) | 2001-06-14 | 2007-04-03 | Bristol-Myers Squibb Company | Polynucleotides encoding human histone deacetylase HDAC9c |
| CN1610696A (zh) | 2001-12-20 | 2005-04-27 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
| JP4836451B2 (ja) | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
| GB0220205D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Neisseria toxin |
| DE60334247D1 (de) | 2002-11-27 | 2010-10-28 | Irm Llc | Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen |
| EP1583773A1 (fr) | 2003-01-07 | 2005-10-12 | Biomerieux | Polypeptides f' du virus de l'hepatite c, epitopes et leurs applications diagnostiques et therapeutiques |
| JP5452835B2 (ja) | 2003-07-15 | 2014-03-26 | 中外製薬株式会社 | 形質転換細胞によるＩｇＭの産生とその定量方法 |
| EP1656151B1 (en) | 2003-08-01 | 2007-09-26 | Enhan Technology Holdings International Co., Ltd. | Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury and proliferation and/or differentiation of neural stem cells in injured spinal cord |
| CN100427505C (zh) | 2004-08-19 | 2008-10-22 | 中国医学科学院基础医学研究所 | 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途 |
| BRPI0517057A (pt) | 2004-11-05 | 2008-09-30 | Palingen Inc | composição para induzir ferimento de membrana celular; composição para aumentar o ferimento da membrana celular em uma célula linfóide; composição para permeabilizar uma célula; composição para induzir ferimento da membrana celular em células b; composição para aumentar o ferimento da membrana celular induzido por um anticorpo de ferimento de membrana celular; método de tratamento de um mamìfero que sofre de uma condição distinta por uma hiperproliferação de células; método para matar uma célula cancerosa; método para induzir ferimento de membrana celular em uma célula linfóide em um paciente humano; método para induzir ferimento da membrana celular; método para permeabilizar uma célula; método de purgar a medula óssea de células b malignas de um paciente com esta necessidade; estojo para determinar o limite da dose para um agente polivalente que induz o ferimento da membrana celular em um mamìfero; estojo para determinar o limite da dose para um anticorpo de ferimento de membrana celular em um mamìfero; uso de um agente polivalente de ferimento de membrana celular; e uso de um anticorpo de ferimento de membrana celular |
| EP1833848A2 (en) | 2004-12-09 | 2007-09-19 | Lajolla Institute for Allergy and Immunology | Novel tnf receptor regulatory domain |
| MX2007008723A (es) | 2005-01-21 | 2007-09-12 | Epitopix Llc | Polipeptidos de yersinia spp y metodos de uso. |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| US20060269556A1 (en) | 2005-04-18 | 2006-11-30 | Karl Nocka | Mast cell activation using siglec 6 antibodies |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| US8088908B2 (en) | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
| US20060269569A1 (en) | 2005-05-16 | 2006-11-30 | Liu Yuen | Universal antioncotic and pain relieving ointment |
| US20060269567A1 (en) | 2005-05-16 | 2006-11-30 | Liu Yuen | Universal detoxifying composition |
| JP5389438B2 (ja) | 2005-05-24 | 2014-01-15 | アメリカ合衆国 | 抗アドヘシンに基づく受動免疫予防物の製造方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| WO2007112146A2 (en) | 2006-01-13 | 2007-10-04 | Irm Llc | Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases |
| CN101074261A (zh) | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
| US8268635B2 (en) | 2006-05-19 | 2012-09-18 | Antonio Ferrante | Methods of identifying agents that selectively activate p38 and/or NKkB signaling |
| EP3805269A1 (en) | 2006-06-12 | 2021-04-14 | Aptevo Research and Development LLC | Single-chain multivalent binding proteins with effector function |
| KR100847010B1 (ko) | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| HUE052220T2 (hu) | 2006-09-08 | 2021-04-28 | Abbvie Bahamas Ltd | Interleukin-13 kötõfehérjék |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| CN101965363A (zh) | 2006-11-02 | 2011-02-02 | 丹尼尔·J·卡鹏 | 具有活动部分的杂合免疫球蛋白 |
| AU2007358569B2 (en) | 2007-09-07 | 2014-09-04 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| CA2706700A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| EP2254592B1 (en) | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| CN102170905B (zh) | 2008-08-01 | 2016-08-03 | 阿克西斯股份有限公司 | 骨关节炎治疗剂及预防剂 |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| JP5851419B2 (ja) | 2009-12-29 | 2016-02-03 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ヘテロダイマー結合タンパク質およびその使用 |
| WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| MX2012011629A (es) | 2010-04-07 | 2013-03-05 | Abbvie Inc | Proteinas de union a tnf-alfa. |
| SI2614082T1 (sl) | 2010-09-09 | 2018-12-31 | Pfizer Inc. | Molekule, ki vežejo 4-1BB |
| JP5918143B2 (ja) | 2010-10-29 | 2016-05-18 | 第一三共株式会社 | 新規抗ｄｒ５抗体 |
| WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| AU2012245309C1 (en) | 2011-04-21 | 2016-07-21 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| US9382319B2 (en) * | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
| CN103974977A (zh) | 2011-09-26 | 2014-08-06 | Jn生物科学有限责任公司 | 杂交恒定区 |
| PE20142245A1 (es) | 2011-10-24 | 2015-01-22 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf e il-17 |
| IN2014MN01781A (enExample) | 2012-02-08 | 2015-07-03 | Igm Biosciences Inc | |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| EP3415167B1 (en) | 2012-08-01 | 2024-05-29 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| JP2015524821A (ja) | 2012-08-02 | 2015-08-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質 |
| US9725517B2 (en) | 2012-10-26 | 2017-08-08 | Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences | Humanized monoclonal antibodies against the extracellular domain of human death receptor 5 |
| US9487773B2 (en) | 2013-03-01 | 2016-11-08 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Cell-based methods for coupling protein interactions and binding molecule selection |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP2994487B1 (en) | 2013-05-07 | 2019-10-09 | F.Hoffmann-La Roche Ag | Trimeric antigen binding molecules |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| DK3041862T3 (da) | 2013-09-05 | 2020-07-27 | Igm Biosciences Inc | Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| WO2015103072A1 (en) | 2013-12-30 | 2015-07-09 | Epimab Biotherapeutics | Fabs-in-tandem immunoglobulin and uses thereof |
| EP3094644B1 (en) | 2014-01-16 | 2019-07-24 | Mondelli, Mario Umberto Franceso | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen |
| DK3105250T3 (da) | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | Multispecifikke iga-bindingsmolekyler |
| CA2943167A1 (en) | 2014-03-24 | 2015-10-01 | University Of Southampton | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| ES2717704T3 (es) | 2014-04-03 | 2019-06-24 | Igm Biosciences Inc | Cadena J modificada |
| EP3204412B1 (en) | 2014-10-08 | 2020-08-19 | F.Hoffmann-La Roche Ag | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents |
| PL3247728T3 (pl) | 2015-01-20 | 2020-11-16 | Igm Biosciences, Inc. | Cząsteczki wiążące receptor nadrodziny czynnika martwicy nowotworów (TNF) i ich stosowanie |
| SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
| SI3265575T1 (sl) | 2015-03-04 | 2021-08-31 | Igm Biosciences, Inc. | Vezne molekule CD20 in njihove uporabe |
| EP3274051A4 (en) | 2015-03-25 | 2018-08-22 | IGM Biosciences A/S | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| JP6811723B2 (ja) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
| AU2016286108B2 (en) | 2015-06-30 | 2021-03-11 | Pfizer Inc. | BTLA fusion protein agonists and uses thereof |
| AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
| SI3355913T1 (sl) | 2015-09-30 | 2025-01-31 | Igm Biosciences, Inc. | Vezalne molekule z modificirano j-verigo |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| KR102343742B1 (ko) | 2016-05-09 | 2021-12-24 | 아이쥐엠 바이오사이언스 인코포레이티드 | 항-pd-l1 항체 |
| US20190330374A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
| WO2018017763A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
| CA3030659A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| WO2018017761A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
| AU2017332452B2 (en) | 2016-09-23 | 2021-01-07 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| CA3091140A1 (en) | 2018-02-26 | 2019-08-29 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| BR112020017296A2 (pt) | 2018-03-01 | 2020-12-29 | Igm Biosciences, Inc. | Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm |
| KR20210083260A (ko) | 2018-10-23 | 2021-07-06 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다가 IgM- 및 IgA-Fc 기반 결합 분자 |
| WO2020163646A1 (en) | 2019-02-08 | 2020-08-13 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
| AU2020329301A1 (en) | 2019-08-15 | 2022-02-17 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| WO2021034646A1 (en) | 2019-08-17 | 2021-02-25 | Igm Biosciences, Inc. | Multimeric bispecific anti-cd123 binding molecules and uses thereof |
| US20220306760A1 (en) | 2019-08-23 | 2022-09-29 | Igm Biosciences, Inc. | Igm glycovariants |
| WO2021055765A2 (en) | 2019-09-19 | 2021-03-25 | Igm Biosciences, Inc. | Multimeric antibodies with enhanced selectivity for cells with high target density |
| WO2021141902A1 (en) | 2020-01-06 | 2021-07-15 | Igm Biosciences, Inc. | Highly sialylated multimeric binding molecules |
| IL297029A (en) | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Multimeric binding compounds as pd-1 agonists |
| KR20230010221A (ko) | 2020-05-12 | 2023-01-18 | 아이쥐엠 바이오사이언스 인코포레이티드 | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 |
| EP4188951A4 (en) | 2020-07-27 | 2024-08-28 | IGM Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| WO2022109023A1 (en) | 2020-11-17 | 2022-05-27 | Igm Biosciences, Inc. | Uses of effector cell engaging molecules with moieties of differing potencies |
| US20220267415A1 (en) | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
| AU2022221633A1 (en) | 2021-02-17 | 2023-08-10 | Igm Biosciences, Inc. | Anti-cd123 binding molecules and uses thereof |
-
2016
- 2016-01-20 PL PL16740686T patent/PL3247728T3/pl unknown
- 2016-01-20 WO PCT/US2016/014153 patent/WO2016118641A1/en not_active Ceased
- 2016-01-20 US US15/544,873 patent/US10689449B2/en active Active
- 2016-01-20 SG SG11201705116SA patent/SG11201705116SA/en unknown
- 2016-01-20 ES ES16740686T patent/ES2806500T3/es active Active
- 2016-01-20 PT PT167406867T patent/PT3247728T/pt unknown
- 2016-01-20 NZ NZ732922A patent/NZ732922A/en unknown
- 2016-01-20 DK DK16740686.7T patent/DK3247728T3/da active
- 2016-01-20 AU AU2016209324A patent/AU2016209324B2/en active Active
- 2016-01-20 IL IL284430A patent/IL284430B2/en unknown
- 2016-01-20 SG SG10202001779UA patent/SG10202001779UA/en unknown
- 2016-01-20 IL IL308212A patent/IL308212A/en unknown
- 2016-01-20 SI SI201630842T patent/SI3247728T1/sl unknown
- 2016-01-20 JP JP2017556795A patent/JP7179464B2/ja active Active
- 2016-01-20 CN CN201680006321.XA patent/CN107207601A/zh active Pending
- 2016-01-20 CA CA2972990A patent/CA2972990A1/en active Pending
- 2016-01-20 HU HUE16740686A patent/HUE051013T2/hu unknown
- 2016-01-20 KR KR1020177022773A patent/KR102435324B1/ko active Active
- 2016-01-20 EP EP16740686.7A patent/EP3247728B1/en active Active
- 2016-01-20 EP EP20168740.7A patent/EP3750918A1/en active Pending
-
2017
- 2017-06-21 IL IL253054A patent/IL253054B/en unknown
- 2017-06-30 US US15/638,748 patent/US9938347B2/en active Active
-
2020
- 2020-02-24 AU AU2020201323A patent/AU2020201323B2/en active Active
- 2020-04-28 US US16/861,102 patent/US11578131B2/en active Active
- 2020-09-23 JP JP2020158581A patent/JP2021006044A/ja active Pending
-
2022
- 2022-09-07 JP JP2022142258A patent/JP7499813B2/ja active Active
- 2022-11-14 US US18/055,340 patent/US20230203173A1/en not_active Abandoned
-
2024
- 2024-06-04 JP JP2024090474A patent/JP2024113039A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503401A5 (enExample) | ||
| JP7499813B2 (ja) | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 | |
| JP2019530640A5 (enExample) | ||
| JP2019528683A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| JP2007530588A5 (enExample) | ||
| CA3224830A1 (en) | Agonistic tnf receptor binding agents | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2019513370A5 (enExample) | ||
| CA3022636A1 (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| WO2014106015A2 (en) | Multivalent binding protein compositions | |
| EP2483310A1 (en) | Bispecific death receptor agonistic antibodies | |
| US20210380691A1 (en) | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders | |
| CA3079363A1 (en) | Multispecific antigen binding proteins | |
| AU2019416503A1 (en) | Antibody fusion protein, preparation method therefor and application thereof | |
| JP2017509323A5 (enExample) | ||
| RU2016132370A (ru) | ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα | |
| CA3205985A1 (en) | Antibodies to tnfr2 and uses thereof | |
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| CN115052888A (zh) | FcγRIIB亲和力增强的抗体Fc区 | |
| TW202306984A (zh) | 抗ｃｄ１３７抗體及使用方法 | |
| KR20210046725A (ko) | 신규 암 면역요법 항체 조성물 | |
| WO2024114676A1 (zh) | Cldn18.2/4-1bb结合蛋白及其医药用途 | |
| JPWO2021050656A5 (enExample) | ||
| CN119894930A (zh) | 一种双特异性抗体及其应用 |